TY - JOUR
T1 - Consensus statement on smoking cessation in patients with pain
AU - Iida, Hiroki
AU - Yamaguchi, Shigeki
AU - Goyagi, Toru
AU - Sugiyama, Yoko
AU - Taniguchi, Chie
AU - Matsubara, Takako
AU - Yamada, Naoto
AU - Yonekura, Hiroshi
AU - Iida, Mami
N1 - Funding Information:
Hiroki Iida: Shionogi Pharmaceutical Co., Ltd. (scholarship donation ¥1,200,000). Yoko Sugiyama: Pfizer Inc. (application grant US $44,536.96), Japan Agricultural Cooperative (funded course ¥18,000,000). Shigeki Yamaguchi: Daiichi Sankyo Co., Ltd. (Per diem allowances (e.g., lecture fees) ¥1,117,573), Hisamitsu Pharmaceutical Co., Inc. (Per diem allowances (e.g., lecture fees) ¥1,128,298).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022
Y1 - 2022
N2 - Smoking is closely associated with the development of various cancers and tobacco-related illnesses such as cardiovascular and respiratory disorders. However, data are scarce on the relationship between smoking and both acute and chronic pain. In addition to nicotine, tobacco smoke contains more than 4000 different compounds. Although nicotine is not the sole cause of smoking-induced diseases, it plays a critical role in pain-related pathophysiology. Despite the acute analgesic effects of nicotine, long-term exposure leads to tolerance and increased pain sensitivity due to nicotinic acetylcholine receptor desensitization and neuronal plastic changes. The purpose of smoking cessation interventions in smoking patients with pain is primarily not only to reduce their pain and associated limitations in activities of daily living, but also to improve the outcomes of underlying pain-causing conditions and reduce the risks of tobacco-related disorders. This statement aims to summarize the available evidence on the impact of smoking on pain and to inform medical professionals of the significance of smoking cessation in patients with pain.
AB - Smoking is closely associated with the development of various cancers and tobacco-related illnesses such as cardiovascular and respiratory disorders. However, data are scarce on the relationship between smoking and both acute and chronic pain. In addition to nicotine, tobacco smoke contains more than 4000 different compounds. Although nicotine is not the sole cause of smoking-induced diseases, it plays a critical role in pain-related pathophysiology. Despite the acute analgesic effects of nicotine, long-term exposure leads to tolerance and increased pain sensitivity due to nicotinic acetylcholine receptor desensitization and neuronal plastic changes. The purpose of smoking cessation interventions in smoking patients with pain is primarily not only to reduce their pain and associated limitations in activities of daily living, but also to improve the outcomes of underlying pain-causing conditions and reduce the risks of tobacco-related disorders. This statement aims to summarize the available evidence on the impact of smoking on pain and to inform medical professionals of the significance of smoking cessation in patients with pain.
UR - http://www.scopus.com/inward/record.url?scp=85137999178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137999178&partnerID=8YFLogxK
U2 - 10.1007/s00540-022-03097-w
DO - 10.1007/s00540-022-03097-w
M3 - Article
C2 - 36069935
AN - SCOPUS:85137999178
JO - Journal of Anesthesia
JF - Journal of Anesthesia
SN - 0913-8668
ER -